120
Participants
Start Date
October 1, 2025
Primary Completion Date
March 14, 2028
Study Completion Date
December 14, 2029
INCA035784
INCA035784 will be administered at protocol defined dose.
RECRUITING
Icahn School of Medicine At Mount Sinai, New York
NOT_YET_RECRUITING
Johns Hopkins University, Baltimore
NOT_YET_RECRUITING
University of North Carolina At Chapel Hill, Chapel Hill
NOT_YET_RECRUITING
Mayo Clinic-Florida, Jacksonville
NOT_YET_RECRUITING
Medical College of Wisconsin, Milwaukee
NOT_YET_RECRUITING
University of Chicago Medical Center, Chicago
NOT_YET_RECRUITING
University of Texas Southwestern Medical Center Harold C Simmons Comprehensive Cancer Center Blood, Dallas
NOT_YET_RECRUITING
South Austin Medical Center, Austin
NOT_YET_RECRUITING
Colorado Blood Cancer Institute, Denver
NOT_YET_RECRUITING
Huntsman Cancer Institute At University of Utah, Salt Lake City
NOT_YET_RECRUITING
Mayo Clinic Hospital, Phoenix
NOT_YET_RECRUITING
Stanford University, Palo Alto
NOT_YET_RECRUITING
Massachusetts General Hospital, Boston
NOT_YET_RECRUITING
Macquarie University Hospital, Sydney
RECRUITING
Royal Adelaide Hospital, Adelaide
NOT_YET_RECRUITING
The Alfred Hospital, Melbourne
RECRUITING
Linear Clinical Research, Nedlands
Lead Sponsor
Incyte Corporation
INDUSTRY